AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7640495
Drug: Alcohol extraction
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol extraction of Abelmoschus manihot, Gliclazide and Captopril tablets
Trial: 7640495
Drug: Gliclazide and
RxNorm normalized name: Gliclazide and metformin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide and Captopril tablets
Trial: 2719459
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg orally
Trial: 2719459
Drug: Amoxicillin 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 3.0 g plus probenecid 1.0 g orally
Trial: 385458
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cimetidine per day
Trial: 385458
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical tablets containing lactose)
Trial: 21086010
Drug: Training with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training with low level laser therapy (LLLT)
Trial: 8151002
Drug: Nicotine skin
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine skin patch
Trial: 15514884
Drug: Profile preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profile preparation of the root canal with maillefer thermafil filling (Group A)
Trial: 15514884
Drug: Profile preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profile preparation of the root canal with iodoform cataplasm and gutta percha filling (Group B)
Trial: 15514884
Drug: Preparation of
RxNorm normalized name: kit for the preparation of Ga-68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation of the root canal with stainless steel hand-operated instruments, iodoform cataplasm and gutta percha filling (Group C)
Trial: 9405581
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of [13C5] and [2H2]folic acid (approximately 500 nmol each)
Trial: 9405581
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of [2H2]folic acid (226 nmol)
Trial: 9405581
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of [13C5]folic acid (1010 nmol)
Trial: 9405581
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of intravenous vs oral doses
Trial: 8131770
Drug: TTS-NG (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTS-NG (transdermal nitroglycerin) 10 mg.24 h-1
Trial: 8131770
Drug: TTS-NG +
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTS-NG + BNZ (benazepril 10 mg b.i.d.)
Trial: 3314877
Drug: Control program
RxNorm normalized name: ZO Skin Health Pigment Control Program Plus Hydroquinone KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control program (no adjunct treatment)
Trial: 31297739
Drug: Transcatheter treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter treatment with MitraClip®
Trial: 31297739
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (optimal medical therapy)
Trial: 27125909
Drug: Ubiquinol-10 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol-10 (150 mg/day)
Trial: 12569288
Drug: Dacarbazine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacarbazine (250 mg/m(2) days 1‐5 every 3 weeks) plus tamoxifen
Trial: 12569288
Drug: Vindesine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesine (3 mg/m(2) every week for 6 weeks, then every 2 weeks) plus tamoxifen
Trial: 1352050
Drug: Remoxipride (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride (150-300 mg daily)
Trial: 6371649
Drug: Bichromatic argon
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bichromatic argon laser therapy (multiple wavelengths: 454.5 nm to 528.7 nm)
Trial: 6371649
Drug: Monochromatic argon
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monochromatic argon laser therapy (green wavelength at 514.5 nm)
Trial: 6371649
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between bichromatic and monochromatic laser therapy
Trial: 29126396
Drug: Structured, individualized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured, individualized endurance training and nutrition education based on the Mediterranean diet for 3 months, plus monthly group training and regular telephone contact during the subsequent 9 months
Trial: 16513672
Drug: Intrabrachial infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrabrachial infusions of noradrenaline (NA)
Trial: 16513672
Drug: Intrabrachial infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrabrachial infusions of tyramine (TYR)
Trial: 12084809
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (2-2.5 mg patches/d)
Trial: 2714912
Drug: oral atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral atenolol (100 mg per day)
Trial: 2714912
Drug: oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral verapamil (80 mg three times per day)
Trial: 318849
Drug: Lignocaine, etidocaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine, etidocaine, and bupivacaine in 10-ml doses of plain solutions
Trial: 31320738
Drug: ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ranibizumab treatment
Trial: 25439413
Drug: ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 4 mg (Group O4)
Trial: 25439413
Drug: ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramosetron 0.3 mg (Group R)
Trial: 25439413
Drug: ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg (Group O8)
Trial: 11180025
Drug: Mizolastine 20
RxNorm normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine 20 mg
Trial: 10336575
Drug: Mizolastine 40
RxNorm normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine 40 mg
Trial: 2044648
Drug: Cholestyramine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (24 g daily in divided doses) plus moderate cholesterol-lowering diet
Trial: 7006620
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg xipamide per day
Trial: 7006620
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg xipamide per day
Trial: 7006620
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of xipamide
Trial: 22720051
Drug: Twice‐weekly, school‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice‐weekly, school‐based jumping regime
Trial: 12455115
Drug: 1% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% ropivacaine without adrenalin but with 10 U/mL of hyaluronidase (Group RH)
Trial: 8905242
Drug: Paracetamol 750
RxNorm normalized name: Hydrocodone bitartrate 7.5 mg and paracetamol 750 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 750 mg
Trial: 8905242
Drug: Paracetamol 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1250 mg
Trial: 8905242
Drug: Paracetamol 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1500 mg
Trial: 1648944
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus infusion of metoclopramide (1 mg/kg, 30 min, every 8 h, day 1-5)
Trial: 1648944
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of metoclopramide (3 mg/kg/24 h, 120 h)
Trial: 1648944
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of metoclopramide
Trial: 1648944
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus infusion of metoclopramide
Trial: 31970581
Drug: Perceived drug-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived drug-related stigma measures
Trial: 31970581
Drug: Internalized drug-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internalized drug-related stigma measures
Trial: 31970581
Drug: Drug-related stigma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-related stigma
Trial: 29846653
Drug: EPA (2.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA (2.7 g/d)
Trial: 28131045
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil (3 g/d)
Trial: 24961021
Drug: 3% modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% modified fluid gel
Trial: 22226431
Drug: Topical eflornithine
RxNorm normalized name: eflornithine Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical eflornithine hydrochloride
Trial: 20074751
Drug: Endothelin‐A subtype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin‐A subtype receptor antagonist sitaxsentan at 1 mg/kg
Trial: 20074751
Drug: Endothelin‐A subtype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin‐A subtype receptor antagonist sitaxsentan at 2 mg/kg
Trial: 17684988
Drug: Agents containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agents containing succinic and fumaric acids (Group 1, n = 11)
Trial: 17684988
Drug: Infusion therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion therapy (Group 2, n = 11)
Trial: 8499823
Drug: Amoxycillin once
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin once daily
Trial: 31729550
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose fentanyl infusion (1 mcg/kg/hr)
Trial: 31729550
Drug: 24% oral
RxNorm normalized name: Entero VU, 24% oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% oral sucrose (2 ml)
Trial: 16182896
Drug: Single 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 20 mg/kg dose of ciprofloxacin
Trial: 16182896
Drug: 12.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg/kg of erythromycin every 6 h for 3 days
Trial: 12468135
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E(2) and 0.5 mg NETA for 28 days
Trial: 12468135
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg CEE for 28 days and 5 mg MG for the final 14 days
Trial: 12468135
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E(2) and 0.5 mg NETA
Trial: 12840859
Drug: Control (natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (natural labor, no drug)
Trial: 6763357
Drug: Albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg (Group A)
Trial: 6763357
Drug: Albendazole 600
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 600 mg (Group B)
Trial: 30794304
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg per day of DHA
Trial: 24188512
Drug: Prolonged Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged Exposure (PE) therapy for PTSD, 10 weekly sessions
Trial: 23064072
Drug: Low-dose FP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose FP chemotherapy (continuous 5-FU 500mg/day with intermittent CDDP 10mg/day)
Trial: 23064072
Drug: Low-dose FP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose FP chemotherapy (same regimen resumed after recurrence)
Trial: 18634707
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lactitol and Lactobacillus acidophilus NCFM, consumed twice daily for 2 weeks
Trial: 18634707
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lactitol and Lactobacillus acidophilus NCFM
Trial: 17497139
Drug: High-dose venlafaxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose venlafaxine
Trial: 17497139
Drug: High-dose sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sertraline
Trial: 21838852
Drug: High-dose citalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose citalopram
Trial: 2205379
Drug: Intraperitoneal rIL‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal rIL‐2 at 8 X 10(6) units/m2/dose
Trial: 2205379
Drug: Intraperitoneal rIL‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal rIL‐2 and LAK infusion
Trial: 2205379
Drug: Intraperitoneal rIL‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal rIL‐2 infusion
Trial: 28242860
Drug: Sleep intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep intervention (sleep and combination)
Trial: 28242860
Drug: FAB intervention
RxNorm normalized name: DIGOXIN IMMUNE FAB
DrugBank: Digoxin Immune Fab (Ovine) (DB00076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAB intervention (FAB and combination)
Trial: 19158369
Drug: Fermagate 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermagate 1 g three times daily
Trial: 19158369
Drug: Fermagate 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermagate 2 g three times daily
Trial: 17359569
Drug: Home health
RxNorm normalized name: SALICYLIC ACID 1.8 g in 100 mL TOPICAL SHAMPOO [Home Health Everclean Antidandruff]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home health care through a combination of traditional face‐to‐face and telemedicine visits (n = 83)
Trial: 11491008
Drug: Mefloquine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (10 mg/kg at 0 h, then 5 mg/kg at 6 h)
Trial: 11491008
Drug: Artesunate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (4 mg/kg on day 0, then 2 mg/kg on day 1 to 4)
Trial: 7979523
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (40 mg/day)
Trial: 7979523
Drug: Oxandrolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (2.5 mg/day)
Trial: 3261651
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (ungrafted arteries)
Trial: 3261651
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (grafted arteries)
Trial: 3261651
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (closed grafts)
Trial: 3261651
Drug: Coronary artery
RxNorm normalized name: Drug-coated coronary artery stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary artery treatment (regardless of type)
Trial: 31144431
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with dapagliflozin 5 mg/d plus saxagliptin 5 mg/d added to metformin
Trial: 31144431
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with dapagliflozin added to metformin
Trial: 31144431
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with saxagliptin added to metformin
Trial: 31144431
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with dapagliflozin
Trial: 31144431
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with saxagliptin
Trial: 26656981
Drug: Integrative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative treatment including moxibustion therapy conducted twice a week for 4 weeks on bilateral acupoints SP6, LR3, and CV4.
Trial: 26656981
Drug: Integrative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative treatment including moxibustion therapy.
Trial: 26656981
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (watchful waiting or oral medication including α blocker, 5α-reductase inhibitors or antimuscarinic drugs).
Trial: 11422959
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation on a weekly basis
Trial: 11422959
Drug: Anthelmintic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthelmintic treatment at the beginning and week 12
Trial: 11422959
Drug: Both iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both iron supplementation and anthelmintic treatment
Trial: 11422959
Drug: Lower haemoglobin
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower haemoglobin values and anaemia (< 120 g/l Hb)
Trial: 9050126
Drug: 10 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ng/ml haloperidol
Trial: 3544626
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE) combined with low-dose heparin (LDH)
Trial: 28946789
Drug: Psychotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy treatment for borderline personality disorder over four months
Trial: 28946789
Drug: Individualized treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatments for personality disorders
Trial: 24962666
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus vitamin D supplementation (1,000 mg calcium per day and 50,000 U vitamin D3 pearl twice during the study)
Trial: 21990519
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment with stenting
Trial: 21990519
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment without stenting
Trial: 20113759
Drug: Interferential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential therapy with amplitude-modulated frequency (100Hz)
Trial: 20113759
Drug: Interferential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential therapy without amplitude-modulated frequency (0Hz)
Trial: 15957994
Drug: Intrapartum fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrapartum fentanyl (dose range 8-500 micrograms)
Trial: 11912393
Drug: Capsaicin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (2 mM in 30 ml ethanol plus 70 ml 0.9% sodium chloride)
Trial: 11912393
Drug: Resiniferatoxin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resiniferatoxin (100 nM in 100 ml 0.9% sodium chloride)
Trial: 9877147
Drug: AT4 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT4 (4 mmol x l(‐1) threshold)
Trial: 8560416
Drug: DDAVP (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP (0.3 microgram/kg intravenous infusion)
Trial: 8560416
Drug: DDAVP (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP (0.3 microgram/kg intravenous infusion) in Group I patients
Trial: 8560416
Drug: DDAVP (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP (0.3 microgram/kg intravenous infusion) in Group II patients
Trial: 8560416
Drug: DDAVP (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP (0.3 microgram/kg intravenous infusion) in Group III patients
Trial: 81125
Drug: Gamma-globulin intramuscularly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-globulin intramuscularly administered 24 hours after infection